Ironwood Pharmaceuticals, Inc.
IRWD
$3.58
-$0.09-2.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.80% | -15.72% | -10.42% | -22.98% | -23.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.80% | -15.72% | -10.42% | -22.98% | -23.18% |
| Cost of Revenue | -20.70% | -14.62% | -21.32% | -17.40% | -4.00% |
| Gross Profit | 32.85% | -16.24% | -5.02% | -25.61% | -30.82% |
| SG&A Expenses | -46.40% | -42.87% | -39.16% | -28.44% | -12.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.46% | -30.52% | -31.26% | -23.42% | -8.61% |
| Operating Income | 171.73% | 23.45% | 51.43% | -21.92% | -49.52% |
| Income Before Tax | 615.41% | 7.40% | 30.74% | -50.17% | 102.38% |
| Income Tax Expenses | 23.05% | -28.47% | -12.95% | -35.65% | -22.29% |
| Earnings from Continuing Operations | 415.90% | 2,629.20% | 1,014.74% | -209.77% | 97.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 415.90% | 2,629.20% | 1,259.11% | -185.59% | 96.93% |
| EBIT | 171.73% | 23.45% | 51.43% | -21.92% | -49.52% |
| EBITDA | 167.11% | 22.84% | 50.22% | -21.64% | -48.81% |
| EPS Basic | 413.15% | 2,778.43% | 1,193.13% | -183.03% | 97.04% |
| Normalized Basic EPS | 279.10% | 30.85% | 62.17% | -36.43% | -75.67% |
| EPS Diluted | 380.01% | 1,972.88% | 629.18% | -252.13% | 96.93% |
| Normalized Diluted EPS | 256.77% | 17.49% | 48.90% | -34.95% | -74.74% |
| Average Basic Shares Outstanding | 1.60% | 1.73% | 1.96% | 2.18% | 2.34% |
| Average Diluted Shares Outstanding | 6.73% | 6.38% | 6.80% | -0.18% | -2.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |